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The relative desirability of an unrelated donor with a bidirectional 1-locus mismatch (1MM-Bi), a 1-locus
mismatch only in the graft-versus-host direction (1MM-GVH), or a 1-locus mismatch only in the host-
versus-graft direction (1MM-HVG) is not yet clear. We analyzed adult patients with leukemia or myelodys-
plastic syndrome who received a ﬁrst allogeneic stem cell transplant from an HLA-A, -B, -C, and -DRB1
matched or 1-allele mismatched unrelated donor in Japan. The effects of 1MM-Bi (n ¼ 1020), 1MM-GVH (n ¼
83), and 1MM-HVG (n ¼ 83) compared with a zero mismatch (0MM) (n ¼ 2570) were analyzed after
adjusting for other signiﬁcant variables. The risk of grades III to IV acute graft-versus-host disease (GVHD)
was higher with marginal signiﬁcance in the 1MM-GVH group than in the 0MM group (hazard ratio, 1.85; P ¼
.014). However, there was no signiﬁcant difference in overall or nonrelapse mortality between the 1MM-GVH
and 0MM groups. There was no signiﬁcant difference in acute GVHD or overall or nonrelapse mortality be-
tween the 1MM-HVG and 0MM groups. The risks of acute GVHD and overall mortality were signiﬁcantly
higher in the 1MM-Bi group than in the 0MM group. These ﬁndings indicate that unrelated donors with
1MM-GVH and 1MM-HVG are both good candidates for patients without an HLA-matched unrelated donor in
a Japanese cohort.
 2015 American Society for Blood and Marrow Transplantation.dgments on page 310.
quests: Yoshinobu Kanda, MD, Division
Center, Jichi Medical University, 1-847
City, Saitama, Japan 330-8503.
in.ac.jp (Y. Kanda).
14.10.015
ty for Blood and Marrow Transplantation.INTRODUCTION
An HLA-identical sibling is the best donor for allogeneic
stem cell transplantation because of the low risk of immune
complications suchas acute graft-versus-hostdisease (GVHD)
and graft rejection. However, for patients without an HLA-
identical sibling, an HLA-A, -B, -C, and -DRB1 allele-matched
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immediate transplant is not necessary [1,2]. Finally, when an
HLA-matched unrelated donor is not available, an HLA 1-
allele mismatched unrelated donor is an attractive donor
source, although the overall survival rate after HLA 1-allele
mismatched unrelated transplantation is 5% to 10% lower
than that after HLA-matched unrelated transplantation [3-5].
Among 1-allele mismatched unrelated donors, the
mismatch is only in the graft-versus-host direction (1MM-
GVH) when a mismatched allele of the donor is homozygous.
On the other hand, the mismatch is only in the host-versus-
graft direction (1MM-HVG) when a mismatched allele of the
recipient is homozygous. The effect of the immune reaction
caused by an HLAmismatch differs according to whether the
mismatch is in the GVH or HVG direction, because a mis-
matched antigen in the GVH direction can be a major target
for donor T cells and can cause GVHD, whereas a mismatched
antigen in the HVG direction can be a major target for the
remaining recipient T cells and can lead to graft rejection. In
related transplantation, the presence of HLA mismatches in
the GVH direction is associated with a higher incidence of
GVHD, whereas the presence of HLA mismatches in the HVG
direction is associated with a higher incidence of rejection
[6-8]. Therefore, from a biological perspective, the impact of
1MM-GVH, 1MM-HVG, or bidirectional 1-locus mismatch
(1MM-Bi) on the clinical outcome should differ, and ques-
tions regarding donor selection priority should arise when
several donor candidates with 1MM-Bi, 1MM-GVH, or 1MM-
HVG are available for patients without an HLA-matched
unrelated donor.
In a recent study by the Center for International Blood and
Marrow Transplant Research (CIBMTR), transplantation from
an unrelated donor with 1MM-Bi or a donor with 1MM-GVH
was signiﬁcantly associated with higher risks of severe acute
GVHD and overall mortality than transplantation from an
unrelated donor without a mismatch at the HLA-A, -B, -C, or
-DRB1 locus (0MM) [9]. However, transplantation from a
donor with 1MM-HVG was not associated with these risks.
Therefore, selection of an unrelated donor with 1MM-HVG is
recommended when an unrelated donor with 0MM is not
available. However, hazard ratios (HRs) of overall and
disease-free survival in the 1MM-HVG group as compared
with the 0MM group were also high (1MM-HVG HR, 1.37
[P¼ .03] and 0MMHR,1.38 [P¼ .013]). Although these values
were not statistically signiﬁcant as deﬁned in that study
(P< .01), these HRs in the 1MM-HVG groupwere comparable
with those in the 1MM-Bi group (1.29 and 1.35, respectively),
suggesting the study may have had insufﬁcient power to
detect a signiﬁcant difference between the 1MM-HVG and
0MM groups. Therefore, the effect of the HLA mismatch di-
rection in unrelated bone marrow transplantation (UBMT)
needs to be validated in other populations. In the present
study, we conducted a retrospective analysis using Japanese
national registry data on 3756 patients who underwent HLA-
matched or 1-allele mismatched UBMT.METHODS
Data Collection
Patients who were at least 16 years of age with acute myelogenous
leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic
syndrome (MDS), or chronic myelogenous leukemia (CML), who received a
ﬁrst BMT from a serologically HLA-A, -B, and -DR matched unrelated donor
between 2000 and 2011, and who had full HLA-A, -B, -C, and -DRB1 allele
data were included in this study. Data were obtained from the Transplant
Registry Uniﬁed Management Program (TRUMP) [10], where all UBMTs are
registered through the Japan Marrow Donor Program (JMDP). We excludedthose who had more than 1-allele mismatch at the HLA-A, -B, -C, or -DRB1
locus; those who lacked data on survival status, survival date, and sex; and
those in whom ex vivo or in vivo T cell depletion was used. As a result, 3756
patients were included in this study. The study was approved by the data
management committee of TRUMP and by the Institutional Review Board of
Saitama Medical Center, Jichi Medical University, where this study was
organized.
Histocompatibility
Histocompatibility data for serological and genetic typing for the HLA-A,
-B, -C, and -DR loci were obtained from the TRUMP database, which includes
HLA allele data determined retrospectively by the JMDP using frozen sam-
ples [11,12]. The extent of HLA testing was exons 2 and 3 for HLA class I and
exon 2 for HLA class II. Exon 4 and exon 3 were additionally analyzed for
classes I and II, respectively, if required. An HLA mismatch in the GVH di-
rection was deﬁned as when the recipient’s antigens or alleles were not
shared by the donor, and a mismatch in the HVG direction was deﬁned as
when the donor’s antigens or alleles were not shared by the recipient.
Endpoints
The primary endpoint of the study was overall survival. Other endpoints
assessed were relapse, nonrelapse mortality, neutrophil engraftment, acute
GVHD, and chronic GVHD. Neutrophil recovery was considered to have
occurred when the absolute neutrophil count exceeded 0.5  109 cells/L for
3 consecutive days after transplantation. The physicians who performed
transplantation at each center diagnosed and graded acute and chronic
GVHD according to the traditional criteria [13,14]. The incidence of chronic
GVHD was evaluated in patients who survived without relapse for more
than 100 days.
Statistical Analysis
The probability of overall survival was estimated according to the
Kaplan-Meier method, and groups were compared using the log-rank test.
The probabilities of relapse, nonrelapse mortality, neutrophil engraftment,
and acute and chronic GVHD were estimated on the basis of cumulative
incidence curves [15]. Competing events were death without relapse for
relapse, relapse for nonrelapse mortality, death without engraftment for
neutrophil engraftment, and death or relapse without GVHD for acute and
chronic GVHD. The groups were compared using Gray’s test [16]. The Cox
proportional hazards model was used to evaluate the effect of confounding
variables on overall survival, whereas Fine and Gray’s proportional hazards
model was used for the other endpoints [17]. Based on the report by the
CIBMTR, we classiﬁed the conditioning regimens as myeloablative if total
body irradiation> 8 Gy, oral busulfan 9mg/kg, intravenous busulfan 7.2
mg/kg, or melphalan > 140 mg/m2 was used in the conditioning regimen;
otherwise, we classiﬁed the conditioning regimen as reduced intensity [18].
For patients with insufﬁcient data regarding the doses of the agents used in
the conditioning regimen, we used the information on conditioning in-
tensity (myeloablative or reduced intensity) reported by the treating clini-
cians. We deﬁned AML and ALL in the ﬁrst or second remission, CML in the
ﬁrst or second chronic phase or accelerated phase, and MDS with refractory
anemia or refractory anemia with ringed sideroblasts as standard-risk dis-
eases and other conditions as high risk.
The following possible confounding variables were considered: the
recipient’s age group (16 to 49 years or 50 years), the recipient’s sex, sex
mismatch between the recipient and donor (match, male [donor]/female
[recipient] or female [donor]/male [recipient]), disease (AML, ALL, CML, or
MDS), disease status before transplantation (standard or high risk), type of
GVHD prophylaxis (cyclosporine based, tacrolimus based, or other/missing),
type of conditioning regimen (myeloablative, reduced intensity, or missing),
and year of transplantation (2000-2005 or 2006-2011). Factors other than
HLA matching were selected in a stepwise manner from the model with a
variable retention criterion of P < .05. We then added HLA matching to the
ﬁnal model. For multiple comparisons, a value of P < .01 was used to
determine statistical signiﬁcance.
All statistical analyses were performed with Stata version 13 (Stata
Corp., College Station, TX) and EZR (Saitama Medical Center, Jichi Medical
University, Saitama, Japan) [19]. EZR is a graphical user interface for R (The R
Foundation for Statistical Computing, version 2.13.0, Vienna, Austria). More
precisely, it is a modiﬁed version of R commander (version 2.0-1) designed
to add statistical functions that are frequently used in biostatistics.
RESULTS
Patient Characteristics
Table 1 shows patient and transplant characteristics.
The median age of recipients at transplantation was 43
years (range, 16 to 77). The diagnosis for transplant was
Table 1
Patient Characteristics
Characteristics 0MM (n ¼ 2570) 1MM-Bi (n ¼ 1020) 1MM-GVH (n ¼ 83) 1MM-HVG (n ¼ 83) P
Median recipient age at transplant, yr (range) 43 (16-77) 41 (16-74) 43 (16-65) 43 (18-71) .037
Recipient age at transplant
16-39 yr 1061 457 32 31 .175
40 þ yr 1509 563 51 52
HLA mismatch
A locus 0 119 11 21
B locus 0 27 0 3
C locus 0 521 47 38
DR locus 0 353 25 21
Recipient sex
Female 1018 423 34 29 .573
Male 1552 597 49 54
Sex mismatch between donor and recipient
Match 1591 617 43 52 .017
Male donorefemale recipient 580 207 17 16
Female donoremale recipient 399 196 23 15
Diagnosis
AML 1329 513 33 49 .137
ALL 647 240 24 17
CML 236 122 11 6
MDS 358 145 15 11
Disease risk at transplant
Standard risk 1659 616 55 46 .188
High risk 832 373 26 33
Missing 79 31 2 4
GVHD prophylaxis
Cyclosporine based 811 299 22 31 .177
Tacrolimus based 1701 704 59 48
Others/missing 58 17 2 4
Conditioning regimen
Meyeloablative 2001 806 64 58 .444
Reduced intensity 486 176 15 22
Missing 83 38 4 3
Transplant year
2000-2005 1147 548 40 47 <.001
2006-2011 1423 472 43 36
Values are total number of cases, unless otherwise noted.
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Two-thirds of the patients had standard-risk diseases.
Tacrolimus-based GVHD prophylaxis was used in 67%.
Transplantation was performed between 2006 and 2011 in
1974 cases (53%).
HLA matching was categorized as follows: HLA match in
both the GVH and HVG directions (0MM, n ¼ 2570, 68%),
bidirectional 1-allele mismatch in the GVH and HVG
directions (1MM-Bi, n ¼ 1020, 27%), 1-allele mismatch in the
GVH direction but 0mismatches in the HVG direction (1MM-
GVH, n¼ 83, 2%), and 1-allele mismatch in the HVG direction
but 0 mismatches in the GVH direction (1MM-HVG, n ¼ 83,
2%). More transplants using a matched unrelated donor with
0MM were performed between 2006 and 2011.Figure 1. Overall survival. The unadjusted probability of overall survival is
shown.Overall Survival
The median follow-up period in survivors was 3.4 years
(range, .7 to 12.6). The unadjusted 3-year overall survival rate
was 55% (95% conﬁdence interval [CI], 52% to 57%) in the
0MM group, 46% (95% CI, 43% to 49%) in the 1MM-Bi group,
62% (95% CI, 50% to 72%) in the 1MM-GVH group, and 52%
(95% CI, 41% to 63%) in the 1MM-HVG group (P < .001,
Figure 1). The risk of overall mortality was signiﬁcantly
higher in the 1MM-Bi group than in the 0MM group (hazard
ratio [HR], 1.31; 95% CI, 1.19 to 1.46; P < .001), whereas there
was no difference between the 0MM group and the 1MM-
GVH group (HR, .97; 95% CI, .70 to 1.34; P¼ .850) or the 1MM-
HVG group (HR, 1.13; 95% CI, .85 to 1.55; P ¼ .439) (Table 2).Nonrelapse Mortality and Relapse
The cumulative incidence of unadjusted 3-year non-
relapse mortality was 24% (95% CI, 22% to 25%) in the 0MM
group, 30% (95% CI, 27% to 33%) in the 1MM-Bi group, 26%
(95% CI, 17% to 36%) in the 1MM-GVH group, and 25% (95% CI,
16% to 35%) in the 1MM-HVG group (P < .001, Figure 2). The
risk of nonrelapse mortality was signiﬁcantly higher in the
Figure 2. Nonrelapse mortality and relapse. The unadjusted incidences of
nonrelapse mortality (A) and relapse (B) are shown.
Table 2
Overall Mortality, Nonrelapse Mortality, and Relapse
HR 95% CI P
Overall mortality*
0MM 1.00 Reference
1MM-Bi 1.31 1.19-1.45 <.001
1MM-GVH .97 .70-1.34 .850
1MM-HVG 1.13 .83-1.52 .439
Nonrelapse mortalityy
0MM 1.00 Reference
1MM-Bi 1.38 1.21-1.59 <.001
1MM-GVH 1.22 .81-1.84 .334
1MM-HVG 1.12 .75-1.69 .575
Relapsez
0MM 1.00 Reference
1MM-Bi .98 .85-1.14 .810
1MM-GVH .78 .48-1.29 .338
1MM-HVG .88 .55-1.43 .614
* Other signiﬁcant variables were the recipient’s age group, sex of the
recipient, diagnosis, and disease risk.
y Other signiﬁcant variables were the recipient’s age group, sex of the
recipient, diagnosis, disease risk, and transplant year.
z Other signiﬁcant variables were diagnosis and disease risk.
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whereas no difference was found between the 0MM group
and the 1MM-GVH group (HR, 1.22; P ¼ .334) or the 1MM-
HVG group (HR, 1.12; P ¼ .575) (Table 2). The cumulative
incidence of unadjusted 3-year relapse was 26% (95% CI, 24%
to 27%) in the 0MM group, 27% (95% CI, 24% to 29%) in the
1MM-Bi group, 21% (95% CI, 12% to 31%) in the 1MM-GVH
group, and 24% (95% CI, 15% to 34%) in the 1MM-HVG group
(P ¼ .635, Figure 2). There was no signiﬁcant difference be-
tween the 0MM group and the other groups in the multi-
variate analysis (Table 2).
Neutrophil Engraftment
The cumulative incidence of neutrophil engraftment at
day 50 was 96% (95% CI, 95% to 96%) in the 0MM group, 94%
(95% CI, 92% to 95%) in the 1MM-Bi group, 100% in the 1MM-
GVH group, and 92% (95% CI, 83% to 96%) in the 1MM-HVG
group (P¼ .224, Figure 3). Therewas no signiﬁcant difference
between the 0MM group and the other groups in the
multivariate analysis (Table 3).
Acute and Chronic GVHD
The unadjusted cumulative incidence of grades III to IV
acute GVHD was 12% (95% CI, 10% to 13%) in the 0MM group,
18% (95% CI, 16% to 20%) in the 1MM-Bi group, 18% (95% CI,
11% to 27%) in the 1MM-GVH group, and 15% (95% CI, 8% to
23%) in the 1MM-HVG group (P < .001, Figure 4). The risk of
grades III to IV acute GVHD was signiﬁcantly higher in the
1MM-Bi group (HR, 1.57; P < .001) and higher in the 1MM-
GVH group with marginal signiﬁcance (HR, 1.85; P ¼ .014)
than in the 0MM group (Table 3). There was no difference
between the 0MM group and the 1MM-HVG group (HR, 1.25;
P ¼ .468). The unadjusted cumulative incidence of chronic
GVHD was 37% (95% CI, 35% to 39%) in the 0MM group, 35%
(95% CI, 32% to 38%) in the 1MM-Bi group, 41% (95% CI, 30% to
52%) in the 1MM-GVH group, and 30% (95% CI, 20% to 41%) in
the 1MM-HVG group (P ¼ .584, Figure 4). No signiﬁcant
difference was found between the 0MM group and the other
groups in the multivariate analysis (Table 3).
DISCUSSION
Using Japanese registry data, we analyzed patients who
received UBMT with either 1MM-GVH or 1MM-HVG andevaluated the impact of 1MM-GVH and 1MM-HVG on the
clinical outcome. The risk of severe acute GVHD in the 1MM-
GVH group tended to be higher than that in the 0MM group.
However, there was no signiﬁcant difference in overall sur-
vival or nonrelapse mortality between the 2 groups. The
overall survival and nonrelapse mortality rates in the 1MM-
HVG group were also comparable with those in the 0MM
group. Unlike the conclusion of the CIBMTR study, there is no
evidence in this study that an unrelated donor with 1MM-
HVG should be prioritized over 1 with 1MM-GVH in a Japa-
nese cohort.
Although the incidence of grades III to IV acute GVHD
tended to be higher in the 1MM-GVH group than in the 0MM
group, this did not translate intoworse overall survival in this
Japanese cohort. In interpreting this ﬁnding, several differ-
ences in patient background between the CIBMTR study [9]
and the present study should be clariﬁed. First, the CIBMTR
study included transplants performed from 1988 to 2009,
whereas our study included transplants performed from
2000 to 2011. Because treatment and supportive care for
transplant-related complications such as GVHD and fungal or
viral infections improved over this decade, the incidence of
nonrelapsemortalitywas shown tobe signiﬁcantly decreased
Figure 4. Acute and chronic GVHD. The unadjusted incidences of grades III to
IV acute GVHD (A) and chronic GVHD (B) are shown.
Figure 3. Neutrophil engraftment. The unadjusted incidence of neutrophil
engraftment is shown.
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developed grades III to IV acute GVHD after HLA 1-allele
mismatched UBMT improved from 32.1% in the period from
1993 to 2001 to 44.4% in the period from 2002 to 2011 [21].
Including only a recent cohort in our studymay have reduced
the impact of acute GVHD on the nonrelapse mortality rate.
The second difference is the deﬁnition of allele mismatch.
We included only patients who received UBMT from HLA-A,
-B, or -DR antigen matched pairs, following the standard
donor selection process of the JMDP, because such a donor
can be found for more than 90% of patients in Japan. In this
process, we start to search for an HLA-A, -B, -C, and -DRB1
matched unrelated donor; if one is not available, we then
search for a 1-allele mismatched donor among HLA-A, -B,
and -DR antigen matched unrelated donor pools. We
generally do not extend the donor search to an HLA-A and -B
antigen mismatched unrelated donor (an HLA-DR antigen
mismatched donor is an exception [22]). Regarding HLA-C
mismatch, 89% of the HLA-C allele mismatches were at the
antigen level in this study. Another CIBMTR study showed no
signiﬁcant differences in overall survival or acute GVHD ratesTable 3
Neutrophil Engraftment, Acute GVHD, and Chronic GVHD
HR 95% CI P
Neutrophil engraftment*
0MM 1.00 Reference
1MM-Bi .94 .88-1.01 .108
1MM-GVH 1.01 .84-1.21 .956
1MM-HVG .97 .78-1.21 .781
Grades III to IV acute GVHDy
0MM 1.00 Reference
1MM-Bi 1.57 1.30-1.90 <.001
1MM-GVH 1.85 1.13-3.01 .014
1MM-HVG 1.25 .69-2.27 .468
Chronic GVHDz
0MM 1.00 Reference
1MM-Bi .97 .85-1.11 .681
1MM-GVH 1.10 .76-1.59 .618
1MM-HVG .88 .57-1.35 .558
* Other signiﬁcant variables were the recipient’s age group, sex of the
recipient, sex mismatch, GVHD prophylaxis, and disease risk.
y Other signiﬁcant variables were the recipient’s age group, sex of the
recipient, sex mismatch, disease risk, and transplant year.
z Another signiﬁcant variable was transplant year.between HLA-A, -B, or -DR 1-antigen and 1-allele mis-
matched transplants [4]. However, the possibility remains
that acute GVHD may have less impact on nonrelapse mor-
tality in 1-allele mismatch transplantation than in 1-antigen
mismatched transplantation in a speciﬁc HLA mismatch
status, such as 1 mismatch only in the GVH direction.
The third difference is in ethnicity. The incidence of se-
vere acute GVHD is higher in White populations than in
Japanese populations in HLA-matched related or unrelated
BMT [23,24], although there was no difference in pediatric
UCBT [25]. Ethnic differences may affect the treatment
response for severe acute GVHD.
The fourth difference is the stem cell source. Both
peripheral blood stem cells (PBSCs) and bone marrow were
included in the CIBMTR study, whereas bone marrow was
exclusively included in our study. Although there is no dif-
ference in the incidence of severe acute GVHD between un-
related PBSC transplantation and BMT [26], the use of PBSCs
might be associated with a lower treatment response for
acute GVHD, leading to a relatively higher incidence of
nonrelapse mortality and overall mortality in aWhite cohort.
The impact of the HLA mismatch direction has also been
evaluated in UCBT. In the New York Blood Center study, UCBT
with a mismatch only in the GVH direction was associated
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UCBT with 1MM-Bi [27], whereas a Japanese study showed
the direction of the HLA mismatch does not signiﬁcantly
affect overall survival [28]. The different ﬁndings in the UCBT
studies as compared with UBMT studies may be partly
attributable to the difference in graft components, that is, a
cord blood unit contains signiﬁcantly fewer T cells and total
nucleated cells than bone marrow or PBSCs and lower fre-
quency of severe GVHD in the UCBT. The counting method of
HLA mismatches was also different. Matching in HLA-A and
HLA-B was counted as antigen level and HLA-C was not
considered. In addition, 2 unidirectional mismatches were
included in the UCBT studies.
We did not ﬁnd any association between neutrophil
engraftment and HLA mismatch in the HVG direction. One
explanation for this observation is that our cohort included
only HLA-A, -B, and -DR antigen-matched pairs, in which
graft failure associated with HLA antibodies against donor-
speciﬁc HLA antigens is less likely to occur [29-31].
However, even in the CIBMTR cohorts that included antigen-
mismatched pairs, no association between graft failure and
HLA mismatch direction was observed.
Each locus mismatch may have a different effect on the
transplant outcome. For example, an HLA-C mismatch in the
GVH direction can be a killer immunoglobulin-like receptor
2DL (KIR2DL) ligand mismatch in the HVG direction in some
patients, and vice versa. In a Japanese population, a KIR2DL
ligand mismatch in the GVH direction, but not that in the
HVG direction, has been shown to be associated with a high
risk of acute GVHD and overall mortality [32]. Therefore, the
adverse impact of an HLA-C mismatch in the HVG direction
may be increased by the presence of a KIR2DL ligand
mismatch in the GVH direction in some patients. However, it
is difﬁcult to test any hypothesis regarding the impact of each
locus mismatch and a KIR2DL ligand mismatch because of
the small sample size in this study.
This study has several limitations inherent to a retro-
spective analysis. First, the heterogeneous backgrounds may
have resulted in a statistical bias, although we tried to reduce
this bias by adjusting the impact in multivariate analyses.
Second, the number of subjects in the 1MM-GVH and 1MM-
HVG groups was limited. Therefore, the results should be
interpreted with caution. Finally, we did not ﬁnd any differ-
ences in any of the outcomes among the 1MM-GVH, 1MM-
HVG, and 1MM-Bi groups (data not shown), partly because of
the small sample size in the 1MM-GVH and 1MM-HVG
groups. Therefore, we could not make any conclusion
regarding the comparison between the 1MM-GVH or 1MM-
HVG and 1MM-Bi groups.
In conclusion, the risk of severe acute GVHD in the 1MM-
GVH group tended to be higher than that in the 0MM group.
However, there were no signiﬁcant differences in overall
survival or nonrelapse mortality between the 0MM and
1MM-GVH or 1MM-HVG groups. Our results suggest that for
patients without a matched sibling or matched unrelated
donor, we can choose either an unrelated donor with 1MM-
GVH or 1 with 1MM-HVG when available.ACKNOWLEDGMENTS
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